Recorded on April 28, 2022 Join CLL Society and PlatformQ Health for this on-demand educational session consisting of 3 chapters: Getting Up-to-Speed on New Data Managing Side Effects of BTK Inhibitors: What, When, How, and WhoTips to Stay on the Patient/Caregiver ‘A Game’ Jennifer Woyach, MD, professor at The
At the American Society of Hematology (ASH) 2021, Dr. Alan Skarbnick, Director of the CLL program at Novant Health Cancer Institute in Charlotte, NC, interviewed Dr. Constantine Tam, a hematologist at the Peter McCallum Cancer Center in Melbourne, Australia. They discussed the results of a phase 1 clinical trial
Dr. Charis Teh and colleagues presented this research at the American Society for Hematology annual meeting, which was held in December 2021 (ASH 2021). Background: Venetoclax is a highly effective treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) that works by inhibiting the BCL2 protein. BCL2
Interprofessional Perspectives on Safety Management with Targeted Therapy for B-Cell Malignancies In an educational program from PeerView and CLL Society, an interprofessional team comprised of a hematologist-oncologist (Anthony R. Mato), cardiologist (Dipti Gupta), oncology nurse (Kristen Battiato), and pharmacist (Amber C. King) take a close look at BTK and
Blocking the B-cell receptor (BCR) with ibrutinib and other BTKi drugs has revolutionized care in CLL. PI3K inhibitors also block that same receptor and are remarkably effective in treating CLL. Join Dr. Ian Flinn who will explain how these treatments work, the common side effects, and what role they
Pushing Therapeutic Boundaries in CLLJoint Live Web Broadcast with CLL Society and PeerView Institute Recorded on June 14, 2021 Continuous or fixed-duration therapy with targeted agents, including BTK and BCL-2 inhibitors, is the new standard for management of chronic lymphocytic leukemia (CLL). New clinical questions that are pushing the
The ECOG (E1912) Phase III, randomized, open label, clinical trial, comparing the efficacy of combination ibrutinib and rituximab with standard chemo-immunotherapy (FCR in patients 70 years of age or younger with previously untreated CLL) was a huge game-changer for CLL patients. We are happy to share with you Dr.
ASH 2019, Dr. John Pagel interviews Dr. Sameer Parikh regarding a clinical trial out of all locations of the Mayo Clinic investigating the potential benefit of early intervention of high-risk CLL and SLL patients, as determined by the Prognostic CLL International Prognostic Index (IPI), with treatment regimens of either
ASH 2019 Drs. Brian Koffman and Richard Furman discuss the effectiveness and tolerability of covalent irreversible BTK inhibitors such as acalabrutinib, ibrutinib, and zanubrutinib, as well as non-covalent, reversible (3rd generation) BTK inhibitors such as vecabrutinib, LOXO 305, and ArQule 561.